Crushed application of sofosbuvir and velpatasvir in a patient with swallowing disorder

Seyen, Minou van; Samson, Anda D.; Cullen, Lorraine; Eastick, Kirstine; Knol, Hanna; Colbers, Angela; Burger, David M.

doi:10.1016/j.ijantimicag.2020.105934

Cited by 5 publications

(9 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comparison of day 15 and day 16 serum concentrations showed similar SOF AUC 0‐4 h, but a moderate decrease in VEL C max and AUC 0‐4 h . However, crushed VEL concentrations were marginally higher than reference data 13 . The authors also conducted an in vitro study examining the extent of adhesion of SOF/VEL to enteral feeding tubes.…”

Section: Discussionmentioning

confidence: 85%

“…SOF/VEL was crushed, dissolved in water, and administered through a PEG tube for 12 weeks with the exception of the dose on day 16, which was swallowed whole. 13 Comparison of day 15 and day 16 serum concentrations showed similar SOF AUC 0-4 h, but a moderate decrease in VEL C max and AUC 0-4 h . However, crushed VEL concentrations were marginally higher than reference data.…”

Section: Sofosbuvir/velpatasvir (Sof/vel)mentioning

confidence: 83%

“…However, a published case report examined the pharmacokinetic changes with crushed administration of SOF/VEL in a patient with dysphagia and their clinical implications. SOF/VEL was crushed, dissolved in water, and administered through a PEG tube for 12 weeks with the exception of the dose on day 16, which was swallowed whole 13 . Comparison of day 15 and day 16 serum concentrations showed similar SOF AUC 0‐4 h, but a moderate decrease in VEL C max and AUC 0‐4 h .…”

Section: Discussionmentioning

confidence: 99%

“…However, crushed VEL concentrations were marginally higher than reference data. 13 The authors also conducted an in vitro study examining the extent of adhesion of SOF/VEL to enteral feeding tubes. They found that SOF did not have significant adsorption, but VEL was more susceptible to adsorption depending on the type of tube used.…”

Section: Sofosbuvir/velpatasvir (Sof/vel)mentioning

confidence: 99%

See 3 more Smart Citations

Elbasvir/grazoprevir administered for 12 weeks via percutaneous endoscopic gastrostomy tube achieves sustained virologic response: A case report and a review of the literature

et al. 2021

View full text Add to dashboard Cite

Enteral tubes are necessary for certain patients; however, medication absorption can be affected by this route of administration potentially resulting in decreased efficacy. All first-line treatments for Hepatitis C Virus (HCV) infection are only available as tablets and may have decreased absorption if administered via an enteral tube.This report describes the first case of a pegylated interferon and ribavirin treatmentexperienced patient who successfully achieved HCV cure after 12 weeks of elbasvir/ grazoprevir administered via percutaneous gastrostomy tube. We further review the available pharmacokinetic and clinical literature regarding administration via enteral feeding tubes for all first-line direct-acting antivirals (DAAs). The literature suggests that crushed administration can be considered for DAAs in patients with gastric access. However, caution should be exercised in patients with extragastric enteral tubes and in those with altered gastrointestinal tract anatomy.

show abstract

Section: Discussionmentioning

confidence: 85%

Section: Sofosbuvir/velpatasvir (Sof/vel)mentioning

confidence: 83%

Section: Discussionmentioning

confidence: 99%

Section: Sofosbuvir/velpatasvir (Sof/vel)mentioning

confidence: 99%

See 2 more Smart Citations

Elbasvir/grazoprevir administered for 12 weeks via percutaneous endoscopic gastrostomy tube achieves sustained virologic response: A case report and a review of the literature

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Clinical guidelines in Western countries recommend 12 weeks of treatment with SOF/VEL plus ribavirin or 24 weeks of treatment with SOF/VEL, with evidence on the effectiveness of 12 weeks of SOF/VEL being limited. Moreover, few reports have assessed the effectiveness of DAAs in patients who have difficulty swallowing tablets [ 4 , 5 , 6 , 7 , 8 , 9 , 10 ], and no studies to date have evaluated SOF/VEL in Japanese patients who have difficulty swallowing tablets.…”

Section: Introductionmentioning

confidence: 99%

Successful Treatment with Crushed Sofosbuvir/Velpatasvir of a Patient with Decompensated Cirrhosis C and Thrombocytopenia

Murayama

Tajiri

Kanegane

et al. 2021

Case Rep Gastroenterol

View full text Add to dashboard Cite

A 36-year-old woman with decompensated liver cirrhosis type C was referred to our hospital to receive antiviral treatment for hepatitis C virus (HCV). She had been diagnosed with intractable epilepsy and cerebral palsy at birth and was managed by central venous nutrition and nasal gastric feeding. At age 34 years, she was diagnosed with thrombocytopenia, probably associated with HCV infection. She showed refractory ascites for several months and was therefore administered crushed sofosbuvir/velpatasvir tablets via a nasal gastric tube. Her HCV infection was successfully eradicated, her ascites disappeared, and thrombocytopenia improved with a marked decrease in platelet-associated IgG.

show abstract

The Use of Hepatitis C Virus–Positive Organs in Hepatitis C Virus–Negative Recipients

Kuntzen

Bagha

2022

Clinics in Liver Disease

View full text Add to dashboard Cite

Crushed application of sofosbuvir and velpatasvir in a patient with swallowing disorder

Cited by 5 publications

References 4 publications

Elbasvir/grazoprevir administered for 12 weeks via percutaneous endoscopic gastrostomy tube achieves sustained virologic response: A case report and a review of the literature

Elbasvir/grazoprevir administered for 12 weeks via percutaneous endoscopic gastrostomy tube achieves sustained virologic response: A case report and a review of the literature

Successful Treatment with Crushed Sofosbuvir/Velpatasvir of a Patient with Decompensated Cirrhosis C and Thrombocytopenia

The Use of Hepatitis C Virus–Positive Organs in Hepatitis C Virus–Negative Recipients

Contact Info

Product

Resources

About